Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
2045-2322
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure ; volume:10 ; number:1 ; day:27 ; month:10 ; year:2020 ; pages:1-11 ; date:12.2020
Scientific reports ; 10, Heft 1 (27.10.2020), 1-11, 12.2020

Creator
Cheng, Tsung-Yi
Lee, Pei-Chang
Chen, Yi-Tzen
Chao, Yee
Hou, Ming-Chih
Huang, Yi-Hsiang
Contributor
SpringerLink (Online service)

DOI
10.1038/s41598-020-75198-z
URN
urn:nbn:de:101:1-2020120621144891337463
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:32 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Cheng, Tsung-Yi
  • Lee, Pei-Chang
  • Chen, Yi-Tzen
  • Chao, Yee
  • Hou, Ming-Chih
  • Huang, Yi-Hsiang
  • SpringerLink (Online service)

Other Objects (12)

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib

LARP4B promotes hepatocellular carcinoma progression and impairs sorafenib efficacy by activating SPINK1-mediated EGFR pathway

LARP4B promotes hepatocellular carcinoma progression and impairs sorafenib efficacy by activating SPINK1-mediated EGFR pathway

MARK1 suppress malignant progression of hepatocellular carcinoma and improves sorafenib resistance through negatively regulating POTEE

MARK1 suppress malignant progression of hepatocellular carcinoma and improves sorafenib resistance through negatively regulating POTEE

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma

NAP1L1 regulates BIRC2 ubiquitination modification via E3 ubiquitin ligase UBR4 and hence determines hepatocellular carcinoma progression

NAP1L1 regulates BIRC2 ubiquitination modification via E3 ubiquitin ligase UBR4 and hence determines hepatocellular carcinoma progression

Cortical branched actin determines cell cycle progression

Cortical branched actin determines cell cycle progression

Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma

Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma

Cytoskeletal gene alterations linked to sorafenib resistance in hepatocellular carcinoma

Cytoskeletal gene alterations linked to sorafenib resistance in hepatocellular carcinoma

Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Is Reversed by SIRT1

Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Is Reversed by SIRT1

CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma

CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma

DDX5 deficiency drives non-canonical NF-κB activation and NRF2 expression, influencing sorafenib response and hepatocellular carcinoma progression

DDX5 deficiency drives non-canonical NF-κB activation and NRF2 expression, influencing sorafenib response and hepatocellular carcinoma progression

CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity

CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity

Related objects